Meniscus Tears
0
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Innate PharmaFrance - Marseille
1 programPromovia Hydro Balance 100 mg, Hyaluronic acid sodium salt and trehaloseN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2026
2027
Innate PharmaPromovia Hydro Balance 100 mg, Hyaluronic acid sodium salt and trehalose
Clinical Trials (1)
Total enrollment: 25 patients across 1 trials
Evaluation of the Performance and Safety of a Single-dose Hyaluronic Acid (Promovia Hydro Balance) in the Treatment of Non-traumatic Degenerative Meniscus Tears
Start: Apr 2026Est. completion: Jan 202725 patients
N/ARecruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 25 patients
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.